Deerfield Management Portfolio holdings
Deerfield Management is an investment firm dedicated to healthcare, backing therapeutics, medical device, diagnostics and digital health companies at every stage, from startups to mature public businesses. Arnold Snider, a former Tiger Management managing director and Kidder Peabody pharmaceutical analyst, founded the firm in 1994 and retired in 2005. James Flynn joined in 2000 and later became chief executive. Its first healthcare innovations fund, raised in 2015, aimed at scientific advances that could lead to new treatments for genetic diseases, cancer and orphan diseases. In 2020 Deerfield took over Melinta Therapeutics, swapping secured debt for all of its equity after Melinta filed for bankruptcy. Its in-house research arm, Deerfield Discovery and Development, moves early-stage therapies from scientific discovery into the clinic.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nevro
NVRO
|
+$48.4M |
| 2 |
PTLA
Portola Pharmaceuticals
PTLA
|
+$46.1M |
| 3 |
TSRO
Tesaro
TSRO
|
+$22.6M |
| 4 |
Audentes Therapeutics
BOLD
|
+$21.3M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$17.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics
HZNP
|
+$143M |
| 2 |
XNPT
XenoPort
XNPT
|
+$81.5M |
| 3 |
TVTY
Tivity Health
TVTY
|
+$49.8M |
| 4 |
ZLTQ
Zeltiq Aesthetics
ZLTQ
|
+$35.4M |
| 5 |
Vanda Pharmaceuticals
VNDA
|
+$34.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.82% |
| 2 | Miscellaneous | 16.84% |
| 3 | Financials | 3.34% |
| 4 | Industrials | 0% |
Similar funds
Deerfield Management's Q3 2016 Portfolio in Review
As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XenoPort, an estimated $81.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Deerfield Management opened a new position in Nevro worth $56M.
- Deerfield Management's largest Q3 2016 buy was Nevro: 536,355 shares worth $56M.
- Deerfield Management added most to Portola Pharmaceuticals in Q3 2016, an estimated $46.1M increase.
- Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics, cutting an estimated $143M.
- Deerfield Management fully exited XenoPort in Q3 2016, selling an estimated $81.5M.
- Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
- Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
- Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.
Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.